Home Bioscience eyes fresh funds
With a focus on France and Germany, the company builder is also closing in on its final two targets.
Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Biopharma's flotation haul creeps higher
Life is returning to the IPO scene, but the recovery is slow and uncertain.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Pfizer’s oral obesity ambitions take a blow
Pfizer’s discontinuation of once-daily lotiglipron hands the advantage back to Lilly.